During the corresponding time, Arrowhead Pharmaceuticals Inc recorded a revenue increase by 171.02 % year on year, sequentially revenue grew by 2.06 %. While revenue at the Arrowhead Pharmaceuticals Inc 's corporate clients
Arrowhead Pharmaceuticals Expands Talent Pool with Strategic Inducement Grants Under NASDAQ Regulations In a significant move to bolster its workforce and enhance its competitive edge, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced the approval of inducement grants for 84 new employees. Announced on October 24, 2025, this initiative by the Company’s Board of Directors aligns with NASDAQ Listing Rule 5635(c)(4), which permits companies to issue equity incentives as a means to attract talent.These inducement grants will provide the new employees with a total of 127,230 restricted stock units (RSUs), a strategic decision made outside of the Company’s existing stockholder-approved equity incent...
Arrowhead Pharmaceuticals Advances Pioneering RNA Interference Therapies Across Multiple Fronts Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), headquartered in Pasadena, California, continues to spearhead innovative therapeutic solutions targeting an array of complex diseases through its RNA interference (RNAi) technology. The company recently made significant strides in the development and clinical evaluation of multiple investigational treatments, poised to potentially alter the therapeutic landscape for both neurodegenerative and complement-mediated disorders.In a decisive step to challenge the pathogenesis of tauopathies, including Alzheimer s disease, Arrowhead has requested regulatory clearance to com...
Arrowhead Pharmaceuticals and Sarepta Therapeutics: Collaborating with Confidence Amid Market Dynamics In the intricate landscape of pharmaceutical collaborations, the relationship between Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) and Sarepta Therapeutics remains robust and on course. This article delves into the status of their ongoing Exclusive License and Collaboration Agreement, while also shedding light on Arrowhead Pharmaceuticals recent market performance. Ongoing Partnership Commitment Arrowhead Pharmaceuticals has recently issued a statement to reaffirm the unwavering commitment both companies have towards their ongoing collaboration. The agreement, which involves conducting clinical and non-cl...
Arrowhead Pharmaceuticals Unveils Groundbreaking Data on Plozasiran at AHA24PASADENA, Calif. Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has taken center stage at the American Heart Association Scientific Sessions 2024 (AHA24) with exciting new data surrounding their investigational treatment plozasiran. The company presented remarkable findings from the Phase 3 PALISADE study, as well as the open-label extension from the Phase 2 MUIR and SHASTA-2 studies, shedding light on the potential of this innovative therapeutic agent in treating patients at risk for cardiovascular diseases.The Phase 3 PALISADE study, which enrolls participants with elevated cardiovascular risk, delivered compelling insights into...
In the year of our Lord eighteen hundred and sixty, the learned men and women of science began to unravel the mysteries of the human body, propelling forward the boundless journey toward the alleviation of maladies that plague mankind. Fast forward to the contemporary age, a veritable Age of Enlightenment in its own right, when the advances in medical science burgeon forth with unprecedented vigor and vitality. In this spirit, let us cast our gaze towards a certain initiative undertaken by Arrowhead Pharmaceuticals, which has recently filed for regulatory clearance to commence a Phase 1/2a clinical trial of ARO-INHBE, a most promising investigational therapeutic designed to combat the affliction of obesity.N...
PASADENA, Calif. Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) unveiled promising new data from their Phase 3 PALISADE study of plozasiran, an investigational treatment for familial chylomicronemia syndrome (FCS), during the European Society of Cardiology (ESC) Congress 2024. FCS is a severe and rare genetic disorder with no currently approved treatments in the United States. The PALISADE study successfully achieved its primary endpoint and all key secondary endpoints, showing statistically significant reductions in triglycerides (TGs) and apolipoprotein B (ApoB). These encouraging results bolster the potential of plozasiran as a groundbreaking therapy for FCS, aiming to address the unmet medical needs of...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), based in Pasadena, California, has announced its intent to advance two promising RNA interference (RNAi)-based candidates, ARO-INHBE and ARO-ALK7, into clinical trials for obesity and metabolic diseases. This development comes on the heels of preclinical data indicating these candidates’ potential efficacy in reducing body weight and fat mass while also preserving lean muscle mass a crucial factor in the treatment of obesity.The molecular premise behind Arrowhead’s new candidates lies in their innovative mechanism of action, which targets specific pathways associated with fat metabolism. This innovative approach could represent a significant advancement in ...
Inducement Grants Approved for New EmployeesArrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), a leading biopharmaceutical company, has made a significant move in retaining and attracting top-tier talent by offering inducement grants to new employees. On July 25, 2024, the company’s Board of Directors approved the issuance of 60,900 restricted stock units (RSUs) to 33 new employees as an inducement for their employment. These grants are consistent with Rule 5635(c)(4) of the NASDAQ Listing Rules. Understanding Rule 5635(c)(4) of the NASDAQ Listing RulesThe NASDAQ Listing Rule 5635(c)(4) permits a company to grant equity awards, such as stock options and restricted stock units, to new hires without prior shar...
In a strategic move to bolster its workforce, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has recently unveiled its plans to enhance employee engagement through inducement grants. On July 25, 2024, the company s Board of Directors approved the issuance of inducement grants to 33 new employees, as permitted by Rule 5635(c)(4) of the NASDAQ Listing Rules. This initiative not only reflects Arrowhead s commitment to attracting top talent but also underscores its innovative approach to compensation in a competitive biotechnology landscape.The grants comprise a substantial allocation of up to 60,900 restricted stock units (RSUs), which serve as a compelling incentive for new hires to engage with the company’s...
Sources:
Arrowhead Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Arrowhead Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Arrowhead Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
